Recently, a publication on genefo.com about a new treatment in development for Phenylketonuria by Danish biotech company MipSalus, raised considerable discussion on social media. It was suggested that this treatment has already been approved in Europe and awaiting approval in the US. The ESPKU have contacted the CEO of MipSalus for clarification. The statement was published without approval and not accurate. For further information please visit http://www.mipsalus.dk. E.S.PKU has been active to gather information on recent social media topics for you. If you have found something PKU-related that you need clarified, feel free to contact us, we will take care of …
